UV1 vaccine combination shows no significant PFS improvement in BRCA wild type recurrent ovarian cancer
Prof Georgina Long speaks to ecancer about the phase III INTerpath-001 trial, which evaluated the personalised mRNA-based neoantigen therapy intismeran autogene combined with pembrolizumab versus pembrolizumab alone as adjuvant treatment for patients with resected stage IIB–IV melanoma.
Among 1,137 patients, the combination significantly improved recurrence-free survival, reducing the risk of recurrence or death by 42%, and distant metastasis-free survival, reducing the risk of distant metastasis or death by 38%.
At 24 months, recurrence-free survival was 82.2% with intismeran plus pembrolizumab compared with 70.0% with pembrolizumab alone.
Prof Long says the combination was generally well tolerated, although grade 3 or higher adverse events were slightly more frequent.
These findings highlight the potential of personalised neoantigen therapy to improve outcomes in high-risk melanoma following surgery.
UV1 vaccine combination shows no significant PFS improvement in BRCA wild type recurrent ovarian cancer
CD19 CD22 bispecific CAR T cell therapy achieves high response rates in R/R large B cell lymphoma
Surovatamig plus rituximab induces high complete response rates in previously untreated follicular lymphoma
Romiplostim thrombopoietin receptor agonist rapidly restores platelet counts in acute ITP in 1L treatment during COVID 19
mRNA-4359 plus pembrolizumab shows high response rates and robust T-cell activation in melanoma
Machine learning models improve prediction of immunotherapy outcomes across multiple cancer types
PRAME-targeted TCR therapy shows high response rates in metastatic uveal melanoma
Adjuvant pembrolizumab in resected merkel cell carcinoma shows improved distant metastasis-free survival
IO102-IO103 cancer vaccine plus pembrolizumab demonstrates PFS benefit in advanced melanoma